AMRN, BMRN & RECAF – Upcoming Class Actions Deadlines: Bronstein, Gewirtz & Grossman, LLC
NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Amarin Corporation plc (NASDAQ: AMRN)
Class Period: December 5, 2018 – June 21, 2021
Deadline: December 20, 2021
For more info: www.bgandg.com/amrn.
The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) there was an increasingly high risk that certain of Amarin’s patents would be invalidated; (2) once the District Court invalidated certain of Amarin’s patents, there was little to no chance of reversing that ruling; (3) Amarin’s litigation was preventing it from effectuating a successful takeover; and (4) Amarin was downplaying the true threat the ongoing ANDA litigation posed to the Company’s business and future prospects.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
Class Period: January 13, 2020 – September 3, 2021
Deadline: December 21, 2021
For more info: www.bgandg.com/bmrn.
The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) BMN 307 was less safe than BioMarin had led investors to believe; (2) BMN 307’s safety profile made it likely that the FDA would place a clinical hold on the Phearless Phase 1/2 study; (3) accordingly, the Company had overstated BMN 307’s clinical and commercial prospects; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Reconnaissance Energy Africa Ltd. f/k/a Lund Enterprises Corp. (OTC: RECAF, LGDOF)
Class Period: February 28, 2019 – September 7, 2021
Deadline: December 27, 2021
For more info: www.bgandg.com/recaf.
The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) ReconAfrica’s plan for using unconventional means for energy extraction (including fracking) in the fragile Kavango area; (2) that ReconAfrica would begin unlicensed drilling tests; (3) that ReconAfrica would illegally use water for well testing; (4) that ReconAfrica would illegally store used water in unlined pools; (5) that ReconAfrica would skirt Namibian law and hire an inadequate and inappropriate consultant; (6) that, as a result, ReconAfrica risked future well, drilling, and water-related licenses in Namibia and Botswana; (7) that, as opposed to its representations, ReconAfrica did not reach out nor provide adequate information (including in relevant local languages) through accessible means to those to be impacted by its testing and potential energy extraction; (8) that ReconAfrica’s interests are in the Owambo Basin, not the so-called Kavango Basin; (9) that ReconAfrica has continuously engaged in stock pumping; and (10) as a result of the foregoing, defendants’ public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | [email protected]
Disclaimer: This content is distributed by The GlobeNewswire 
